SCHEMBL1639476

SCHEMBL1639476

CN(C)c1ccc2c(c1)Cc1ccccc1-2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.58
CYP3A4 P08684 3/20 0.58
CYP2D6 P10635 2/20 0.58
CYP2C9 P11712 2/20 0.58
CYP2C19 P33261 2/20 0.58
HSD17B10 Q99714 2/20 0.58
HIF1A Q16665 1/20 0.54
ALDH1A1 P00352 2/20 0.53
MAPT P10636 2/20 0.53
HPGD P15428 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
KDM4E B2RXH2 1/20 0.53
LMNA P02545 1/20 0.53
TSHR P16473 1/20 0.51
ATM Q13315 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
SRD5A2 P31213 1/20 0.47
MAOA P21397 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2868061 0.98 CYP1A2 (0.56) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL5532334 0.92 CYP1A2 (0.50) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL2864685 0.91 CYP1A2 (0.49) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4886295 0.90 ALDH1A1 (0.46) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL17264178 0.89 CYP1A2 (0.58) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL17904143 0.84 CYP1A2 (0.54) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL30572795 0.83 CYP1A2 (0.43) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL29068490 0.83 CYP1A2 (0.43) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4886479 0.81 ALDH1A1 (0.46) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL29354370 0.81 ALDH1A1 (0.46) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772009-B2 Room temperature phosphorescence apparatus and methods SCR Research, LLC (US) 2010-08-10 US claimed
WO-2007061574-A2 ROOM TEMPERATURE PHOSPHORESCENCE APPARATUS AND METHODS SCA RESEARCH, LLC (US) 2007-05-31 WO claimed
US-20070117215-A1 Room temperature phosphorescence apparatus and methods POLYMER CONCEPTS TECHNOLOGIES PBY, INC. 2007-05-24 US claimed
EP-0667562-B1 Charge injection barrier for positive charging organic photoconductor HEWLETT PACKARD CO (US) 2001-03-21 EP claimed
US-5663030-A A PHENYL OR NORBORNANE DERIVATIVE AS AN ADDITIVE TO REDUCE HEAT AND ENERGY REQUIRED TO FUSE THE TONER AND TO REDUCE JAMMING OF THE EQUIPMENT XEROX CORPORATION (US) 1997-09-02 US claimed
EP-3553151-A1 PHOSPHORESCENT SUBSTANCE AND PHOSPHORESCENT ELEMENT Kyushu University, National University Corporation (JP) 2019-10-16 EP disclosed
US-8536242-B2 Photocurable composition SEKISUI CHEMICAL CO., LTD. (JP) 2013-09-17 US disclosed
US-20110097669-A1 PHOTOCURABLE COMPOSITION SEKISUI CHEMICAL CO., LTD. (JP) 2011-04-28 US disclosed
US-7772009-B2 Room temperature phosphorescence apparatus and methods SCR Research, LLC (US) 2010-08-10 US disclosed
US-20070254889-A1 Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2007-11-01 US disclosed
WO-2007061574-A2 ROOM TEMPERATURE PHOSPHORESCENCE APPARATUS AND METHODS SCA RESEARCH, LLC (US) 2007-05-31 WO disclosed
US-20070117215-A1 Room temperature phosphorescence apparatus and methods POLYMER CONCEPTS TECHNOLOGIES PBY, INC. 2007-05-24 US disclosed
EP-0849292-A1 Olefin polymerisation catalysts and processes for producing olefin polymers TOSOH CORPORATION (JP) 1998-06-24 EP disclosed
US-5710222-A CATALYTIC POLYMERIZATION OF PROPYLENE WITH METALLOCENE COMPOUND WITH GROUP IVB METAL AND EXTRATION FINA TECHNOLOGY, INC. (US) 1998-01-20 US disclosed
US-5688735-A COORDINATION CATALYST FINA TECHNOLOGY, INC. (US) 1997-11-18 US disclosed
EP-0773239-A2 Method for controlling the melting points and molecular weights of syndiotactic polyolefins using metallocene catalyst systems FINA TECHNOLOGY, INC. (US) 1997-05-14 EP disclosed
EP-0773238-A2 Method for controlling the melting points and molecular weights of syndiotactic polyolefins using metallocene catalyst systems FINA TECHNOLOGY, INC. (US) 1997-05-14 EP disclosed
EP-0709393-A2 Olefin polymerization catalyst and process for producing olefin polymer TOSOH CORPORATION (JP) 1996-05-01 EP disclosed
EP-0667562-A2 Charge injection barrier for positive charging organic photoconductor Hewlett-Packard Company (US) 1995-08-16 EP disclosed
EP-0577581-A2 Method for controlling the melting points and molecular weights of syndiotactic polyolefins using metallocene catalyst systems FINA TECHNOLOGY, INC. (US) 1994-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254889-A1 Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease APP, BACE1, IAPP CYP1A2 1291/4885CYP3A4 946/4885CYP2D6 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.